Door still open for agreed takeover of Fisons

Drugs: Hopes fade for white knight in pounds 1.7bn bid as analysts pred ict return of merger mania

MATHEW HORSMAN

Hopes that a white knight might emerge to save Fisons from a hostile pounds 1.7bn bid launched by Rhone-Poulenc Rorer faded yesterday, as at least one competitor, Astra, ruled itself out and Fisons' shares fell 51/2p to end the day at 259p. But RPR senior management left the door open for an agreed offer, lauding the target company's chief executive and suggesting talks could resume.

Commenting on RPR's offer document, published yesterday, Robert Cawthorn, RPR's chairman, reiterated that the 240p a share offer fully valued Fisons, based on publicly available information. He said that Stuart Wallis, Fisons' chief executive, had done an excellent job restructuring his company and he remained "surprised and disappointed" that talks on an agreed deal had failed.

"In these situations, hostile bids can often become agreed bids," Mr Cawthorn said, hinting he would be prepared to meet Mr Wallis again. Fisons, which now has two weeks to publish its defence, had no comment.

Meanwhile, shares in the pharmaceuticals sector on both sides of the Atlantic rose yesterday, as analysts predicted the $200bn-a-year pharmaceuticals industry will again be gripped by merger mania.

Companies big, medium-sized and small are all struggling with the need to contain costs and expand market share. Analysts expect that the top 10 companies, which now control 37 per cent of the market, might take as much as a 50 per cent by the end of the decade.

Nigel Barnes, analyst with Merrill Lynch, says the action will be driven by the need for new products. "In the next five years, there will be a difference between those companies with a range of products and those without. The market is likely to prefer companies with a strong new product flow."

The pharmaceuticals team at NatWest Securities, meanwhile, say cost-cutting will be an equally important influence on company strategy. They expect sales forces to be further pruned, either by companies acting on their own or through mergers like that between Upjohn and Pharmacia, worth $13bn, which is expected to lead to savings of $500m.

"There is still fat in the industry, and consolidation will help you cut some of that," said RPR's Mr Cawthorn. But he stressed that "innovation is the driving force. Eventually the cost squeeze won't be able to cut costs further."

Innovation was the stated reason for Glaxo's pounds 9bn purchase of Wellcome earlier this year. Armed with a portfolio of products soon to be beyond their patent protection, and dependent on just four drugs for 80 per cent of profits, Glaxo was desperate for new products.

But most companies are far more diversified, with a range of drugs in various therapeutic fields. RPR, for example, derived 80 per cent of its profits from 80 different products last year. The company has set out to focus in four or five niche areas, leading with asthma medicine. Fisons' expertise in this field is its main attraction.

Given the varying reasons why companies either merge or seek strategic partners, picking likely winners in the pharmaceutical business is tricky. Likely success stories in the 1990s include Britain's Zeneca, widely tipped as a potential acquisition, and Merck, the US giant.

Analyst agree research and development is key, and companies that spend significantly on developing new products - particularly those associated with gene therapy - will be best placed. They also like firms with good geographic spread, particularly a strong presence in the US market, responsible for 40 per cent of all drug sales.

Pharmacia's merger with Upjohn, unveiled at the weekend, meets the diversification test: the Swedish concern gets a US presence, while Upjohn gains access to Pharmacia's impressive new product list. But is the merger mania a sign the industry is about to return to the heady days of the 1980s? Analysts are split: NatWest calls for a return to annual sales growth rates of 10 per cent by 2000, but others are more cautious.

The industry's fortunes are intimately tied to the political climate. Spiralling health care costs, along with a restructuring of the health care sector in North America and in Europe, saw the growth in spending on drugs tempered sharply in the early 1990s.

But cost consciousness may end up helping the pharmaceuticals business, analysts predict. An ageing population, coupled with pressures to introduce more preventive care in place of expensive hospitalisation, may give the drugs sector pride of place in health care.

Comment, page 17

Pharmaceuticals industry: the global deals

July 93 Merck buys Medco pounds 3.8bn

May 94 Roche buys Syntex pounds 3.4bn

May 94 Sandoz buys Gerber pounds 2.4bn

May 94 SKB buys Diversified Pharmaceuticals pounds 1.4bn

May 94 Hoechst buys Marion Merrell Dow pounds 4.6bn

July 94 Eli Lilly buys PCS pounds 2.6bn

Aug 94 American Home Products buys Cyanamid pounds 6.3bn

Aug 94 SKB buys Sterling Winthrop pounds 1.9bn

Mar 95 Glaxo buys Wellcome pounds 9.0bn

Aug 95 Rhone-Poulenc Rorer hostile offer Fisons pounds 1.7bn

Aug 95 Pharmacia agreed merger Upjohn pounds 8.4bn

PROMOTED VIDEO
Arts and Entertainment
Rita Ora will replace Kylie Minogue as a judge on The Voice 2015
tv
Life and Style
tech
Life and Style
Alan Turing, who was convicted of gross indecency in 1952, was granted a royal pardon last year
life
Arts and Entertainment
Sheridan Smith as Cilla Black and Ed Stoppard as her manager Brian Epstein
tvCilla Episode 2 review: Grit under the glamour in part two of biopic series starring Sheridan Smith
Life and Style
life
Arts and Entertainment
Tennis player Andy Murray's mum Judy has been paired with Anton du Beke for Strictly Come Dancing. 'I'm absolutely delighted,' she said.
tvJudy Murray 'struggling' to let Anton Du Beke take control on Strictly
Life and Style
Vote with your wallet: the app can help shoppers feel more informed about items on sale
lifeNew app reveals political leanings of food companies
News
ebooksAn unforgettable anthology of contemporary reportage
Arts and Entertainment
The cover of Dark Side of the Moon
musicCan 'The Endless River' carry on the tradition? See for yourself
Sport
New Zealand fly-half Aaron Cruden pictured in The Zookeeper's Son on a late-night drinking session
rugby
Extras
indybest
Voices
A new app has been launched that enables people to have a cuddle from a stranger
voicesMaybe the new app will make it more normal to reach out to strangers
Arts and Entertainment
Salmond told a Scottish television chat show in 2001that he would also sit in front of a mirror and say things like,
tvCelebrity Trekkies from Alex Salmond to Barack Obama
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

IT Project manager - Web E-commerce

£65000 Per Annum Benefits + bonus: Clearwater People Solutions Ltd: If you are...

Trainee / Experienced Recruitment Consultants

£20000 - £25000 per annum + OTE £40,000: SThree: SThree are a global FTSE 250 ...

Trainee Recruitment Consultant - Soho

£20000 - £25000 per annum + OTE £40000: SThree: As a Recruitment Consultant, y...

Trainee Recruitment Consultants - Banking & Finance

£20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...

Day In a Page

Secret politics of the weekly shop

The politics of the weekly shop

New app reveals political leanings of food companies
Beam me up, Scottie!

Beam me up, Scottie!

Celebrity Trekkies from Alex Salmond to Barack Obama
Beware Wet Paint: The ICA's latest ambitious exhibition

Beware Wet Paint

The ICA's latest ambitious exhibition
Pink Floyd have produced some of rock's greatest ever album covers

Pink Floyd have produced some of rock's greatest ever album covers

Can 'The Endless River' carry on the tradition?
Sanctuary for the suicidal

Sanctuary for the suicidal

One mother's story of how London charity Maytree helped her son with his depression
A roller-coaster tale from the 'voice of a generation'

Not That Kind of Girl:

A roller-coaster tale from 'voice of a generation' Lena Dunham
London is not bedlam or a cradle of vice. In fact it, as much as anywhere, deserves independence

London is not bedlam or a cradle of vice

In fact it, as much as anywhere, deserves independence
Vivienne Westwood 'didn’t want' relationship with Malcolm McLaren

Vivienne Westwood 'didn’t want' relationship with McLaren

Designer 'felt pressured' into going out with Sex Pistols manager
Jourdan Dunn: Model mother

Model mother

Jordan Dunn became one of the best-paid models in the world
Apple still coolest brand – despite U2 PR disaster

Apple still the coolest brand

Despite PR disaster of free U2 album
Scottish referendum: The Yes vote was the love that dared speak its name, but it was not to be

Despite the result, this is the end of the status quo

Boyd Tonkin on the fall-out from the Scottish referendum
Manolo Blahnik: The high priest of heels talks flats, Englishness, and why he loves Mary Beard

Manolo Blahnik: Flats, Englishness, and Mary Beard

The shoe designer who has been dubbed 'the patron saint of the stiletto'
The Beatles biographer reveals exclusive original manuscripts of some of the best pop songs ever written

Scrambled eggs and LSD

Behind The Beatles' lyrics - thanks to Hunter Davis's original manuscript copies
'Normcore' fashion: Blending in is the new standing out in latest catwalk non-trend

'Normcore': Blending in is the new standing out

Just when fashion was in grave danger of running out of trends, it only went and invented the non-trend. Rebecca Gonsalves investigates
Dance’s new leading ladies fight back: How female vocalists are now writing their own hits

New leading ladies of dance fight back

How female vocalists are now writing their own hits